The protein Interleukin-6 (IL-6) can take on different functions in cells, depending on how it activates the cells. If it activates cells via the classical signalling path, it helps with the regeneration of tissue, and is indispensable for fighting bacterial infections. However, if it activates cells via so-called ‘trans-signalling’, the protein propels inflammations. In the Journal of Biological Chemistry, scientists at Kiel University have now shown that human immune cells have a built-in protective mechanism which prevents them being activated via trans-signalling.
The protein Interleukin-6 (IL-6) unleashes its different effects by binding with Interleukin-6 receptors (IL-6R). These receptors exist in two versions: membrane-bound and soluble. The membrane-bound forms of the receptor are only found in very few cells in the human body. Through ‘classical signalling’, the regenerative properties of IL-6 are activated. In contrast, the soluble forms of the receptor can activate practically all the cells in the body unhindered, via the ‘trans-signalling’.
Monocytes (leukocytes/ white blood cells), excrete a lot of soluble long gp130 and are thereby very well protected. They lose this ability almost completely when they differentiate into macrophages.
Dr. Christoph Garbers
“It is assumed that this signalling path, in particular, is responsible for triggering the inflammation-boosting activities of IL-6. Therefore, specifically blocking this 'trans-signalling' represents a potential therapeutic option,” said Dr. Christoph Garbers from the Institute of Biochemistry at Kiel University. Blocking this signalling path significantly improves the symptoms of many inflammatory diseases, and is used for treating rheumatoid arthritis, for example. To date, only one antibody has been approved for use which blocks the IL-6R, and thereby stops the activity of the protein.
Together with colleagues from Copenhagen and Hamburg, the Kiel researchers were now able to show that immune cells also have a built-in protective mechanism, to protect themselves from uncontrolled activation. For this purpose, they secrete soluble forms of the signal transducer gp130, which are able to bind with the complex comprising the protein IL-6 and the receptor sIL-6R, and thereby neutralise its activating effect.
It was already known in scientific circles that there are three forms of the soluble gp130 with different lengths. “However, no-one had previously investigated which cells can secrete which forms and, more importantly, why there are forms of different lengths in the first place,” said Garbers. The length of the gp130 forms influences the stability and effectiveness of the receptor: longer forms can block IL-6 trans-signalling more effectively than shorter ones.
“We think that the shorter receptors are used for fine-tuning. As such, the cell has different adjustment mechanisms to defend itself against uncontrolled activation.” Whether or not this blockage can also be externally controlled is one of the topics that the researchers want to investigate next. “If we could stimulate cells to excrete much more of the long forms of gp130, this could be used in the treatment of inflammatory diseases.”
The research team discovered even more about the gp130 receptor: not only can it work differently; it is differentially expressed in a cell-type specific manner. “Interestingly, different immune cells display a different pattern of expression of the three soluble gp130 forms. This means that the cells have differing abilities to protect themselves against IL-6 trans-signalling,” said Garbers. “It is especially conspicuous that monocytes, which are leukocytes, or white blood cells, excrete a lot of soluble gp130 in its longest form, and are thereby very well protected – but they lose this ability completely when they differentiate into macrophages.”
What has not yet been investigated is how the gp130 pattern changes during illnesses. “Next, we would like to see whether changes occur during inflammatory diseases. If, for example, we find that more shorter forms are excreted, it would explain why the protein IL-6 has such pro-inflammatory effects,” said Garbers, looking ahead.
Janina Wolf, Georg H. Waetzig, Athena Chalaris, Torsten M. Reinheimer, Henning Wege, Stefan Rose-John; Christoph Garbers: Different soluble forms of the interleukin-6 family signal transducer gp130 fine-tune the blockade of interleukin-6 trans-signaling; The Journal of Biological Chemistry, doi: 10.1074/jbc.M116.718551
Photos are available for download under:
Microscopic recordings show monocytes (left), which scientists differentiated over ten days into macrophages by adding cytosin M-CSF.
Image/Copyright: Dr. Christoph Garbers
Monocytes, which are leukocytes, or white blood cells, excrete a lot of soluble gp130 in its longest form, and are thereby very well protected – but they lose this ability almost completely when they differentiate into macrophages.
Graphic / Copyright: Dr. Christoph Garbers
Dr. Christoph Garbers
Institute of Biochemistry
Phone: +49 (0)431/880 - 1676
Press, Communication and Marketing, Dr Boris Pawlowski
Postal address: D-24098 Kiel, Germany,
Telephone: +49 (0)431 880-2104, Fax: +49 (0)431 880-1355
E-mail: firstname.lastname@example.org Internet: www.uni-kiel.de
Text: Julia Siekmann
Dr. Boris Pawlowski | Christian-Albrechts-Universität zu Kiel
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy